Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q05639
UPID:
EF1A2_HUMAN
Alternative names:
Eukaryotic elongation factor 1 A-2; Statin-S1
Alternative UPACC:
Q05639; B5BUF3; E1P5J1; P54266; Q0VGC7
Background:
Elongation factor 1-alpha 2 (EF1A2), also known as Eukaryotic elongation factor 1 A-2 and Statin-S1, plays a crucial role in protein synthesis. It promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes, facilitating the elongation phase of protein biosynthesis. This protein's unique functions underscore its importance in cellular mechanisms.
Therapeutic significance:
EF1A2 is implicated in severe neurological disorders, including Developmental and epileptic encephalopathy 33 and Intellectual developmental disorder, autosomal dominant 38. These associations highlight the protein's potential as a target for therapeutic intervention, aiming to alleviate the symptoms and progression of these debilitating conditions.